Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Latest Articles
Submit an article Journal homepage
8
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Admissions for posttransplant lymphoproliferative disorder: a 9-year longitudinal analysis of the National (Nationwide) Inpatient Sample

Zain El-amira Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan, USACorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0001-7649-5634
, MDORCID Icon,
Abdur Jamilb Division of Internal Medicine, Samaritan Medical Center, Watertown, New York, USA
, MD,
Dhanshree Solankic Research Update Organization, Houston, Texas, USA
, MBA, MHA,
Uvesh Mansurid Department of Medicine, Medstar Harbor Hospital, Baltimore, Maryland, USA
, MD, MPH,
Midhun Mathewe Virtua Hospitalists, Marlton, New Jersey, USA
, MD,
Jagmeet Singhf Division of Nephrology, Guthrie Robert Packer Hospital, Sayre, Pennsylvania, USA
, MD,
Shehroz Aslamb Division of Internal Medicine, Samaritan Medical Center, Watertown, New York, USA
, MD,
Hamza Akramb Division of Internal Medicine, Samaritan Medical Center, Watertown, New York, USA
, MD,
Shobha Mandalg Hospitalist Department, Guthrie Robert Packer Hospital, Sayre, Pennsylvania, USA
, MD &
Asim Kichloob Division of Internal Medicine, Samaritan Medical Center, Watertown, New York, USA
, MD show all
Received 28 Feb 2024, Accepted 24 Jun 2024, Published online: 11 Jul 2024

  • Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc. 1969;1(1):106–112.
  • Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13652. doi:10.1111/ctr.13652.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569.
  • Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(2):222–230. doi:10.1046/j.1600-6143.2003.00325.x.
  • Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342(8886-8887):1514–1516. doi:10.1016/S0140-6736(05)80084-4.
  • Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis. 2001;3(2):70–78. doi:10.1034/j.1399-3062.2001.003002070.x.
  • Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87(9):3633–3639. doi:10.1182/blood.V87.9.3633.bloodjournal8793633.
  • Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71(5):1234–1243. doi:10.1182/blood.V71.5.1234.1234.
  • Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A. Post-transplantation lymphoproliferative disorders: current concepts and future therapeutic approaches. World J Transplant. 2020;10(2):29–46. doi:10.5500/wjt.v10.i2.29.
  • Banks CA, Meier JD, Stallworth CR, White DR. Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature. Ann Otol Rhinol Laryngol. 2012;121(5):291–295. doi:10.1177/000348941212100502.
  • Zimmermann H, Xu H, Barlev A, et al. Burden of hospitalizations due to Epstein-Barr virus-driven post-transplant lymphoproliferative disorder (EBV + PTLD) in patients who failed first line rituximab or rituximab plus chemotherapy following solid organ transplant (Post-SOT): a retrospective chart review study of German PTLD registry. Blood. 2019;134(Supp 1):65–65. doi:10.1182/blood-2019-124583.
  • Habermann TM, Fama A, Ristow KM, et al. Clinical characteristics and outcomes of an analysis of a single institution experience of the 2017 World Health Organization (WHO) classification of post-transplant lymphoproliferative disorders (PTLD). Blood. 2018;132(Supp 1):456–456. / doi:10.1182/blood-2018-99-113667.
  • Samant H, Vaitla P, Kothadia JP. Posttransplant lymphoproliferative disorders. In StatPearls. Treasure Island, FL: StatPearls Publishing; 2023. http://www.ncbi.nlm.nih.gov/books/NBK513249/. Accessed November 30, 2023.
  • Kaur S, Shah P, Diaz Duque AE, Shah DP. Post-transplant lymphoproliferative disorder after solid organ transplant: from epidemiology to survival outcomes from 2000 – 2022. Blood. 2022;140(Supp 1):1074–1075. doi:10.1182/blood-2022-170919.
  • Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2(1):15088. doi:10.1038/nrdp.2015.88.
  • Trappe R, Oertel S, Leblond V, et al; German PTLD Study Group, European PTLD Network. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 2012;13(2):196–206. doi:10.1016/S1470-2045(11)70300-X.
  • Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol. 2000;24(3):375–385. doi:10.1097/00000478-200003000-00006.
  • Leblond V, Davi F, Charlotte F, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol. 1998;16(6):2052–2059. doi:10.1200/JCO.1998.16.6.2052.
  • Smets F, Latinne D, Bazin H, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation. 2002;73(10):1603–1610. doi:10.1097/00007890-200205270-00014.
  • Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation. 2001;72(6):1012–1019. doi:10.1097/00007890-200109270-00006.
  • Watson C, Xu H, Princic N, Sruti I, Barlev A. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants. J Med Econ. 2020;23(10):1159–1167. doi:10.1080/13696998.2020.1793765.
  • Hart A, Ahn YS, Watson C, et al. Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status. J Med Econ. 2021;24(1):620–627. doi:10.1080/13696998.2021.1915793.
  • Agency for Healthcare Research and Quality. HCUP National Inpatient Database. doi:10.57761/37HY-TW64.
  • Healthcare Cost and Utilization Project. NIS Database Documentation. Accessed April 4, 2023.
  • “Healthcare Cost and Utilization Project. Overview of National (Nationwide) Inpatient Sample (NIS). https://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed April 1, 2023.
  • Healthcare Cost and Utilization Project. NIS Description of Data Elements. https://www.hcup-us.ahrq.gov/db/nation/nis/nisdde.jsp. Accessed April 6, 2023.
  • Healthcare Cost and Utilization Project. Healthcare Cost and Utilization Project Data Use Agreement Course. https://www.hcup-us.ahrq.gov/DUA/dua_508/DUA508version.jsp. Accessed March 15, 2023.
  • Howell DC. Chi-square test: analysis of contingency tables. In: International Encyclopedia of Statistical Science. 2011: 250–252.
  • Nahm FS. Nonparametric statistical tests for the continuous data: the basic concept and the practical use. Korean J Anesthesiol. 2016;69(1):8–14. doi:10.4097/kjae.2016.69.1.8.
  • Akinyemiju T, Sakhuja S, Vin-Raviv N. Racial and socio-economic disparities in breast cancer hospitalization outcomes by insurance status. Cancer Epidemiol. 2016;43:63–69. doi:10.1016/j.canep.2016.06.011.
  • Solanki S, Chakinala RC, Haq KF, et al. Inpatient burden of gastric cancer in the United States. Ann Transl Med. 2019;7(23):772–772. doi:10.21037/atm.2019.11.54.
  • Dahiya DS, Inamdar S, Perisetti A, et al. Decreasing length of stay and inpatient mortality associated with pancreatic cancer hospitalizations: A United States national survey from 2008 to 2017. Pancreatology. 2022;22(5):590–597. doi:10.1016/j.pan.2022.04.008.
  • Alam ST, Dongarwar D, Lopez E, et al. Disparities in mortality among acute myeloid leukemia-related hospitalizations. Cancer Med. 2023;12(3):3387–3394. doi:10.1002/cam4.5084.
  • Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2417–2426. doi:10.3324/haematol.2020.275958.
  • Lameire N, Vanholder R, Van Biesen W, Benoit D. Acute kidney injury in critically ill cancer patients: an update. Crit Care. 2016;20(1):209. doi:10.1186/s13054-016-1382-6.
  • Mohammed T, Singh M, Tiu JG, Kim AS. Etiology and management of hypertension in patients with cancer. Cardiooncology. 2021;7(1):14. doi:10.1186/s40959-021-00101-2.
  • Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13(3):R64. doi:10.1186/bcr2901.
  • Caillard S, Lamy FX, Quelen C, et al; French Transplant Centers. Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas. Am J Transplant. 2012;12(3):682–693. doi:10.1111/j.1600-6143.2011.03896.x.
  • Kasiske BL, Kukla A, Thomas D, et al. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. Am J Kidney Dis. 2011;58(6):971–980. doi:10.1053/j.ajkd.2011.07.015.
  • Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin’s lymphoma (United States). Cancer Causes Control. 2006;17(5):647–654. doi:10.1007/s10552-005-0502-4.
  • Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28(6):1038–1046. doi:10.1200/JCO.2009.25.4961.
  • Bishnoi R, Bajwa R, Franke AJ, et al. Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Exp Hematol Oncol. 2017;6(1):26. doi:10.1186/s40164-017-0087-0.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.